SYRE · Insider trading · 13F holders · Congress trades
Spyre Therapeutics, Inc. (SYRE)
Who is buying and selling SYRE: company insiders on SEC Form 4, hedge funds and superinvestors on Form 13F, and members of Congress under the STOCK Act. Every figure links to the filing or page it comes from.
- 13F filers holding
- 28
- Insider buys, 90 days
- $0
- Insider sales, 90 days
- $16.9M
- Congress trades, 12 months
- 0
SYRE at a glance
- Between Aug 1, 2026 and Oct 29, 2026, 4 SYRE insiders filed 9 sales worth $16.9M on SEC Form 4, and no open-market purchases; 9 of the sales were pre-planned under Rule 10b5-1.
- 28 13F filers hold SYRE among their 50 largest positions, worth $2.7B combined, including Joseph Edelman. The biggest bets by portfolio weight are Monashee Investment Management LLC (8.2%), Venrock Adviser, LLC (8.0%) and Tang Capital Management LLC (7.7%). In their latest 13Fs, 3 managers opened a new position and 3 added to one.
- No member of Congress has disclosed a trade in SYRE.
- SYRE last closed at $98.96 on Oct 29, 2026.
SYRE insider trading
Between Aug 1, 2026 and Oct 29, 2026, 4 SYRE insiders filed 9 sales worth $16.9M on SEC Form 4, and no open-market purchases; 9 of the sales were pre-planned under Rule 10b5-1.
| Filed | Insider | Role | Trade | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | King-Jones Heidy | See Remarks | Sale10b5-1 | 28,933 | $91.03 | $2.6M | SEC |
| Oct 2, 2026 | Burrows Scott L | Chief Financial Officer | Sale10b5-1 | 25,000 | $90.47 | $2.3M | SEC |
| Oct 2, 2026 | Turtle Cameron | Chief Executive Officer, Director | Sale10b5-1 | 15,000 | $92.01 | $1.4M | SEC |
| Sep 3, 2026 | King-Jones Heidy | See Remarks | Sale10b5-1 | 28,399 | $87.35 | $2.5M | SEC |
| Sep 3, 2026 | Burrows Scott L | Chief Financial Officer | Sale10b5-1 | 25,732 | $88.75 | $2.3M | SEC |
| Sep 3, 2026 | Turtle Cameron | Chief Executive Officer, Director | Sale10b5-1 | 15,000 | $87.29 | $1.3M | SEC |
| Aug 10, 2026 | Albers Jeffrey W. | Director | Sale10b5-1 | 23,000 | $104.53 | $2.4M | SEC |
| Aug 5, 2026 | Turtle Cameron | Chief Executive Officer, Director | Sale10b5-1 | 15,000 | $95.51 | $1.4M | SEC |
| Aug 5, 2026 | Burrows Scott L | Chief Financial Officer | Sale10b5-1 | 7,500 | $95.57 | $717K | SEC |
Who owns SYRE? Hedge funds and superinvestors
28 13F filers hold SYRE among their 50 largest positions, worth $2.7B combined, including Joseph Edelman. The biggest bets by portfolio weight are Monashee Investment Management LLC (8.2%), Venrock Adviser, LLC (8.0%) and Tang Capital Management LLC (7.7%). In their latest 13Fs, 3 managers opened a new position and 3 added to one.
Superinvestors holding SYRE: Joseph Edelman 6.0%
| Manager | % of portfolio | Value | Shares | Last quarter | 13F |
|---|---|---|---|---|---|
| Joseph EdelmanHedge fund | 6.0% | $383.5M | 4,319,496 | +14.2% shares | Q2 2026 |
| Rtw Investments, LPHedge fund | 3.2% | $377.5M | 4,251,996 | +1.9% shares | Q2 2026 |
| Paradigm Biocapital Advisors LPHedge fund | 6.4% | $341.0M | 3,840,778 | +96.2% shares | Q2 2026 |
| Venrock Adviser, LLCHedge fund | 8.0% | $265.0M | 2,985,448 | -19.0% shares | Q2 2026 |
| Driehaus Capital Management LLCHedge fund | 1.4% | $248.5M | 2,799,166 | +0.3% shares | Q2 2026 |
| TCG Crossover Management, LLCHedge fund | 4.1% | $168.7M | 1,900,582 | +0.0% shares | Q2 2026 |
| Tang Capital Management LLCHedge fund | 7.7% | $168.0M | 1,892,200 | +0.0% shares | Q2 2026 |
| Remedium Capital Partners, LLCInstitutional asset manager | 28.8% | $130.0M | 1,464,169 | +0.5% shares | Q2 2026 |
| Affinity Asset Advisors, LLCHedge fund | 5.6% | $113.6M | 1,279,134 | +0.0% shares | Q2 2026 |
| Siren, L.L.C.Investment manager | 1.7% | $86.0M | 968,598 | +18.3% shares | Q2 2026 |
| Braidwell LPHedge fund | 3.0% | $78.1M | 879,467 | -5.7% shares | Q2 2026 |
| Commodore Capital LPHedge fund | 4.5% | $75.2M | 846,786 | -55.7% shares | Q2 2026 |
| Emerald Advisers, LLCInstitutional asset manager | 1.2% | $50.4M | 567,430 | -7.5% shares | Q2 2026 |
| Emerald Mutual Fund Advisers TrustMutual fund manager | 1.3% | $35.6M | 401,271 | -1.7% shares | Q2 2026 |
| Integral Health Asset Management, LLCHedge fund | 1.2% | $28.9M | 325,000 | — | Q2 2026 |
| ADAR1 Capital Management, LLCHedge fund | 1.2% | $25.2M | 283,982 | -16.1% shares | Q2 2026 |
| Cormorant Asset Management, LPHedge fund | 1.0% | $20.0M | 225,000 | New | Q2 2026 |
| Seven Grand Managers, LLCHedge fund | 0.8% | $20.0M | 225,000 | — | Q2 2026 |
| Rhenman & Partners Asset Management ABHedge fund | 1.0% | $10.6M | 119,300 | — | Q2 2026 |
| Stempoint Capital LPHedge fund | 1.6% | $9.5M | 106,926 | -36.2% shares | Q2 2026 |
| Boxer Capital Management, LLCHedge fund | 0.7% | $8.9M | 100,000 | — | Q2 2026 |
| HighVista Strategies LLCHedge fund | 1.6% | $6.9M | 77,807 | -46.8% shares | Q2 2026 |
| B Group, Inc.Hedge fund | 3.5% | $6.2M | 70,000 | -30.0% shares | Q2 2026 |
| Silverarc Capital Management, LLCHedge fund | 0.6% | $5.3M | 59,959 | -67.9% shares | Q2 2026 |
| Atle Fund Management ABAsset manager | 1.4% | $5.1M | 57,030 | -9.1% shares | Q2 2026 |
| Monashee Investment Management LLCInstitutional asset manager | 8.2% | $4.4M | 50,000 | New | Q2 2026 |
| Diadema Partners LPHedge fund | 0.5% | $1.3M | 15,000 | — | Q2 2026 |
| Artia Global Partners LPHedge fund | 0.1% | $355K | 4,000 | New | Q2 2026 |
Each manager counts with its latest 13F (Q2 2026: 28). Screen SYRE in the grand portfolio →
SYRE stock trades by members of Congress
No member of Congress has disclosed a trade in SYRE.
Analysis mentioning SYRE
Posts from the blog that cover Spyre Therapeutics, Inc., newest first.
SYRE questions and answers
Are insiders buying SYRE stock?
Between Aug 1, 2026 and Oct 29, 2026, 4 SYRE insiders filed 9 sales worth $16.9M on SEC Form 4, and no open-market purchases; 9 of the sales were pre-planned under Rule 10b5-1.
Which hedge funds own SYRE?
28 13F filers hold SYRE among their 50 largest positions, worth $2.7B combined, including Joseph Edelman. The biggest bets by portfolio weight are Monashee Investment Management LLC (8.2%), Venrock Adviser, LLC (8.0%) and Tang Capital Management LLC (7.7%). In their latest 13Fs, 3 managers opened a new position and 3 added to one.
Has Congress traded SYRE?
No member of Congress has disclosed a trade in SYRE.
Who is the largest holder of SYRE?
Among 13F filers, Joseph Edelman reports the largest SYRE position, $383.5M (4,319,496 shares) in its Q2 2026 13F. The biggest bet by portfolio weight is Monashee Investment Management LLC's: 8.2% of its portfolio.
Cite or share this
Free to use with a link back. The data updates every filing day.